ClinicalTrials.gg
CompletedNCT00983853Updated Oct 10, 2013Results posted

Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

A Phase 2 interventional study of telaprevir or matching placebo and telaprevir or matching placebo in Hepatitis C and HIV Infections, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 16 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-10-10.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies testing peginterferon alfa-2a in Hepatitis C — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C.

Enrollment
26th of 49
62 · median 64
Started
2009
with 3 others
Phase 2
13 of 49
none open now
Registered
28th of 49
by date
Lead sponsor
7 of 49
Vertex Pharmaceuticals Incorporated

Among the 49 studies testing peginterferon alfa-2a in Hepatitis C, this one is the 26th largest by enrollment, is one of 4 that started in 2009, is one of 13 in phase 2, and was the 28th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 49 studies testing peginterferon alfa-2a in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 49 studies testing peginterferon alfa-2a in Hepatitis C as a file.
02

Study summary

The purpose of this study is to determine whether the combination of telaprevir, peginterferon alfa-2a, and ribavirin is safe and effective in treating hepatitis C virus (HCV) infection in subjects who are infected with both HCV and human immunodeficiency virus (HIV).

03

Conditions studied

  • Hepatitis C
  • HIV Infections

Keywords

  • VX-950
  • INCIVEK
  • INCIVO
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic, genotype 1, with detectable HCV RNA
  • -1 infection for >6 months
  • Documentation of a liver within 1 year before the screening visit showing evidence of hepatitis (demonstrated by inflammation and/or fibrosis)

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with any approved or drug or drug regimen for the treatment of
  • Previous treatment with interferon or ribavirin
  • Evidence of hepatic decompensation in cirrhotic subjects
  • Subjects who have participated in a clinical study involving administration of an investigational drug within 2 months
  • Part A only: subjects who have been on a HAART regimen within 12 weeks before study start
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Part A

    The dose of ribavirin used (fixed versus weight-based) is region dependent

    Drug: telaprevir or matching placebo · Biological: peginterferon alfa-2a · Drug: ribavirin (fixed dose) · Drug: ribavirin (weight-based dose)

  • Experimental
    Part B

    The dose of ribavirin used (fixed versus weight-based) is region dependent

    Drug: telaprevir or matching placebo · Biological: peginterferon alfa-2a · Drug: ribavirin (fixed dose) · Drug: ribavirin (weight-based dose)

Interventions

  • Drugtelaprevir or matching placebo

    Tablet, Oral, 750 mg, q8h, 12 weeks

  • Drugtelaprevir or matching placebo

    Tablet, Oral, 750 mg or 1125 mg, q8h, 12 weeks

  • Subcutaneous injection, 180 μg, once weekly, 48 weeks

  • Tablet, Oral, 800 mg, b.i.d., 48 weeks

  • Tablet, Oral, 1000 mg for subjects weighing \<75 kg or 1200 mg for subjects weighing ≥75 kg, b.i.d., 48 weeks

06

What researchers measure

Primary outcomes

  1. Proportion of Subjects Achieving Undetectable HCV RNA at Week 12

    Time frame: 12 weeks after first dose of study drug

Secondary outcomes

  1. Proportion of Subjects Achieving Undetectable HCV RNA at Week 4 and Week 12

    number of subjects with undetectable HCV RNA

    Time frame: 4 and 12 weeks after the first dose of study drug

  2. Proportion of Subjects Who Have Undetectable HCV RNA 12 Weeks (SVR12) and 24 Weeks (SVR24) After Last Planned Dose of Study Treatment

    Time frame: 12 weeks after last dose of study drug

  3. Effect of Efavirenz-based (EFV) and Atazanavir-based (ATV/r) Highly Active Antiretroviral Therapy(HAART) on Telaprevir Exposure

    Time frame: through 12 weeks after first dose of study drug

  4. Median Trough Plasma Concentration (Ctrough) Ratios of Efavirenz and Tenofovir (Part B Only, Subjects on EFV-based HAART)

    Ctrough ratio of HAART medication with telaprevir (test) and without telaprevir (reference)

    Time frame: through 12 weeks after first dose of study drug

  5. Median Trough Plasma Concentration (Ctrough) Ratios of Atazanavir (ATZ), Ritonavir, and Tenofovir (Part B Only, Subjects on ATV-based HAART)

    Ctrough of HAART medication with telaprevir (test) and without telaprevir (reference)

    Time frame: through 12 weeks after first dose of study drug

07

Results

Posted Oct 10, 2013

Participant flow

Participant flow — Overall Study
MilestonePart A: T/PRPart A: Pbo/PRPart B: EFV-based HAART + T/PRPart B: EFV-based HAART + Pbo/PRPart B: ATV/R-based HAART + T/PRPart B: ATV/R-based HAART + Pbo/PR
Started77178158
Completed65146127
Not completed123231
Withdrew: Lost to follow-up112221
Withdrew: Withdrawal by subject001010
Withdrew: Unable to come to study follow-up visits010000

Outcome measures

PrimaryProportion of Subjects Achieving Undetectable HCV RNA at Week 12
Time frame:
12 weeks after first dose of study drug
Reported as:
Number · participants
Proportion of Subjects Achieving Undetectable HCV RNA at Week 12
participantsPart A: T/PRPart A: Pbo/PRPart B: EFV-based HAART + T/PRPart B: EFV-based HAART + Pbo/PRPart B: ATV/R-based HAART + T/PRPart B: ATV/R-based HAART + Pbo/PR
Proportion of Subjects Achieving Undetectable HCV RNA at Week 1262142102
SecondaryProportion of Subjects Achieving Undetectable HCV RNA at Week 4 and Week 12

number of subjects with undetectable HCV RNA

Time frame:
4 and 12 weeks after the first dose of study drug
Reported as:
Number · participants
Proportion of Subjects Achieving Undetectable HCV RNA at Week 4 and Week 12
participantsPart A: T/PRPart A: Pbo/PRPart B: EFV-based HAART + T/PRPart B: EFV-based HAART + Pbo/PRPart B: ATV/R-based HAART + T/PRPart B: ATV/R-based HAART + Pbo/PR
Week 4 (RVR)5012090
Weeks 4 and 12 (eRVR)4012070
SecondaryProportion of Subjects Who Have Undetectable HCV RNA 12 Weeks (SVR12) and 24 Weeks (SVR24) After Last Planned Dose of Study Treatment
Time frame:
12 weeks after last dose of study drug
Reported as:
Number · participants
Proportion of Subjects Who Have Undetectable HCV RNA 12 Weeks (SVR12) and 24 Weeks (SVR24) After Last Planned Dose of Study Treatment
participantsPart A: T/PRPart A: Pbo/PRPart B: EFV-based HAART + T/PRPart B: EFV-based HAART + Pbo/PRPart B: ATV/R-based HAART + T/PRPart B: ATV/R-based HAART + Pbo/PR
SVR1252114124
SVR2452114124
SecondaryEffect of Efavirenz-based (EFV) and Atazanavir-based (ATV/r) Highly Active Antiretroviral Therapy(HAART) on Telaprevir Exposure
Time frame:
through 12 weeks after first dose of study drug
Reported as:
Least squares mean · ratio (test/reference)
Effect of Efavirenz-based (EFV) and Atazanavir-based (ATV/r) Highly Active Antiretroviral Therapy(HAART) on Telaprevir Exposure
ratio (test/reference)EFV-based (Test, N=15) vs No HAART (Reference, N=7)ATV/R-based (Test, N=13) vs No HAART (Reference, N=7)
Cmin0.8842 (0.5467 to 1.4300)1.3059 (0.7981 to 2.1367)
Cavg0.9610 (0.6615 to 1.3961)1.0930 (0.7456 to 1.6023)
Cmax1.0061 (0.7306 to 1.3855)1.0075 (0.7260 to 1.3982)
SecondaryMedian Trough Plasma Concentration (Ctrough) Ratios of Efavirenz and Tenofovir (Part B Only, Subjects on EFV-based HAART)

Ctrough ratio of HAART medication with telaprevir (test) and without telaprevir (reference)

Time frame:
through 12 weeks after first dose of study drug
Reported as:
Median · ratio (test/reference)
Median Trough Plasma Concentration (Ctrough) Ratios of Efavirenz and Tenofovir (Part B Only, Subjects on EFV-based HAART)
ratio (test/reference)T/PRPbo/PR
Efavirenz0.94 (0.42 to 2.84)0.79 (0.48 to 1.48)
Tenofovir1.06 (0.46 to 17.4)0.64 (0.30 to 2.01)
SecondaryMedian Trough Plasma Concentration (Ctrough) Ratios of Atazanavir (ATZ), Ritonavir, and Tenofovir (Part B Only, Subjects on ATV-based HAART)

Ctrough of HAART medication with telaprevir (test) and without telaprevir (reference)

Time frame:
through 12 weeks after first dose of study drug
Reported as:
Median · ratio (test/reference)
Median Trough Plasma Concentration (Ctrough) Ratios of Atazanavir (ATZ), Ritonavir, and Tenofovir (Part B Only, Subjects on ATV-based HAART)
ratio (test/reference)T/PRPbo/PR
Atazanavir (N=12 T/PR, N=6 Pbo/PR)1.16 (0.39 to 45.0)1.03 (0.49 to 2.05)
Tenofovir (N=13 T/PR, N=7 Pbo/PR)0.75 (0.28 to 40.7)0.93 (0.55 to 1.68)
Ritonavir (N=9 T/PR, N=7 Pbo/PR)0.72 (0.08 to 4.40)0.74 (0.21 to 4.20)

Adverse events

Collected over first dose of study drug until 4 weeks after the last dose of study drug. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
T/PR—7/38 (18.4%)38/38 (100%)
Total PR—2/22 (9.1%)22/22 (100%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventT/PRTotal PR
AppendicitisInfections and infestations0/381/22
AnaemiaBlood and lymphatic system disorders0/381/22
PeritonitisGastrointestinal disorders0/381/22
Groin InfectionInfections and infestations1/380/22
Pyelonephritis AcuteInfections and infestations1/380/22
Cellulitis StaphylococcalInfections and infestations1/380/22
Staphylococcal AbscessInfections and infestations1/380/22
Staphylococcal InfectionInfections and infestations1/380/22
Hemolytic AnemiaBlood and lymphatic system disorders1/380/22
Acute Myocardial InfarctionCardiac disorders1/380/22
Most frequent other events
Showing 10 of 54
Most frequent other events
EventT/PRTotal PR
FatigueGeneral disorders16/389/22
PruritusSkin and subcutaneous tissue disorders15/382/22
HeadacheNervous system disorders14/386/22
NauseaGastrointestinal disorders13/385/22
DiarrhoeaGastrointestinal disorders9/384/22
NeutropeniaBlood and lymphatic system disorders9/385/22
InsomniaPsychiatric disorders5/385/22
MyalgiaMusculoskeletal and connective tissue disorders6/385/22
Weight DecreasedInvestigations5/385/22
PyrexiaGeneral disorders8/382/22

Baseline characteristics

All randomized subjects who received at least 1 dose of study drug

Age Continuous
Age Continuous(years)Part A: T/PRPart A: Pbo/PRPart B: EFV-based HAART + T/PRPart B: EFV-based HAART + Pbo/PRPart B: ATV/R-based HAART + T/PRPart B: ATV/R-based HAART + Pbo/PRTotal
median (min, max)39.4 (34 to 50)47.5 (42 to 65)47.5 (31 to 57)47.0 (31 to 53)52.0 (36 to 59)39.0 (26 to 53)44.5 (26 to 65)
Sex: Female, Male
Sex: Female, Male(Participants)Part A: T/PRPart A: Pbo/PRPart B: EFV-based HAART + T/PRPart B: EFV-based HAART + Pbo/PRPart B: ATV/R-based HAART + T/PRPart B: ATV/R-based HAART + Pbo/PRTotal
Female1201217
Male6416713753
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: T/PRPart A: Pbo/PRPart B: EFV-based HAART + T/PRPart B: EFV-based HAART + Pbo/PRPart B: ATV/R-based HAART + T/PRPart B: ATV/R-based HAART + Pbo/PRTotal
Hispanic or Latino32513317
Not Hispanic or Latino4410712542
Unknown or Not Reported0010001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Part A: T/PRPart A: Pbo/PRPart B: EFV-based HAART + T/PRPart B: EFV-based HAART + Pbo/PRPart B: ATV/R-based HAART + T/PRPart B: ATV/R-based HAART + Pbo/PRTotal
White2312513742
Black/African American43332116
American Indian/Alaska Native1000001
Other0010001
Region of Enrollment
Region of Enrollment(participants)Part A: T/PRPart A: Pbo/PRPart B: EFV-based HAART + T/PRPart B: EFV-based HAART + Pbo/PRPart B: ATV/R-based HAART + T/PRPart B: ATV/R-based HAART + Pbo/PRTotal
North America751389446
United States751389446
Europe01306414
Germany0010113
Spain0120339
France0000202
08

Study locations

16 sites
  • Beverly Hills, California 90211, United States
  • San Diego, California 92093, United States
  • San Francisco, California 94110, United States
  • Miami, Florida 33125, United States
  • Orlando, Florida 32803, United States
  • Chicago, Illinois 60612, United States
  • Baltimore, Maryland 21287, United States
  • Boston, Massachusetts 02114, United States
  • New York, New York 10029, United States
  • Cincinnati, Ohio 45267, United States
  • Dallas, Texas 75204, United States
  • Paris, France
  • Bonn-Venusberg, Germany
  • Hamburg, Germany
  • Barcelona, Spain
  • Madrid, Spain
09

References and documents

Publications

  • Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, Gharakhanian S, McCallister S, Henshaw J, Girard PM, Adiwijaya B, Garg V, Rubin RA, Adda N, Soriano V. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med. 2013 Jul 16;159(2):86-96. doi: 10.7326/0003-4819-159-2-201307160-00654. PubMed 23685940 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009 and a primary completion of Mar 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2013, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2009
First posted
Sep 24, 2009
Start
Oct 2009
Primary completionActual
Mar 2012
Results first posted
Oct 10, 2013
Last update
Oct 10, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00983853
Collaborators
Tibotec Pharmaceutical Limited
Responsible party
Sponsor
First posted
Sep 24, 2009
Start date
Oct 2009
Primary completion
Mar 2012
Results posted
Oct 10, 2013
Last update
Oct 10, 2013

Study contacts

Medical Monitor
study director · Vertex Pharmaceuticals Incorporated

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2a · Ribavirin

Start the discussion